According to filings with the U.S. Securities and Exchange Commission, Nectero Medical is raising up to $96,636,154.00 in new funding. Sources indicate that as part of senior management Chief Financial Officer, Bryan Ziegler played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Nectero Medical
Nectero Medical is developing a novel treatment to stabilize growth and prevent rupture of mid-sized abdominal aortic aneurysms (AAA). The Nectero EAST, or Endovascular Aneurysm Stabilization Treatment System, delivers a compound with a proprietary molecule known as a Stabilizer Agent to the site of the aneurysm. The Stabilizing Agent: Inhibits further breakdown of the aneurysm by disrupting the aortic degradation process. Strengthens the vessel wall by cross-linking within the tissue; this wall strengthening lowers the risk of rupture. Our technology allows for earlier intervention in a much safer manner; this can prevent or significantly delay the need for major endovascular (EVAR) or surgical repair. By preventing further degradation of the aneurysm and strengthening the aortic tissue around the aneurysm, many patients can live out their normal life span and never need to face the challenges of EVAR or Surgical repair.

To learn more about Nectero Medical, visit http://necteromedical.com/

Contact:
Bryan Ziegler, Chief Financial Officer
866-755-4744
https://www.linkedin.com/in/bryan-ziegler-76574a16/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.